Zomal TS

Zomal TS (Targeted/Triple Strength) is a fixed-dose Artemisinin-based Combination Therapy (ACT) antimalarial formulated to deliver rapid parasite clearance and extended prophylaxis against early reinfection. It combines two complementary active pharmaceutical ingredients: dihydroartemisinin (DHA) and piperaquine phosphate.

• Dihydroartemisinin (80 mg): The primary active metabolite of all artemisinin derivatives. It acts rapidly against blood-stage trophozoites by reacting with intra-parasitic heme iron to generate short-lived free radicals. This causes fast parasite biomass destruction and swift clinical fever clearance within hours.

• Piperaquine Phosphate (640 mg): A long-acting bisquinoline antimalarial derivative. It accumulates within the parasite’s acidic food vacuole and inhibits the polymerization of toxic free heme into inert hemozoin. The resulting accumulation of toxic heme causes parasite cell destruction, providing extended therapeutic coverage to clear residual parasites and prevent disease relapse.

The TS (Targeted Strength) formulation consolidates higher concentrations of active ingredients (80 mg DHA / 640 mg piperaquine per unit) compared to standard 40 mg / 320 mg formulations. This allows adult patients to complete their 3-day treatment course with a reduced total pill count.

Primary Medical Indications

Zomal TS is indicated for adult and adolescent populations (weighing 35 kg or more) for the treatment of acute parasitic infections:

• Uncomplicated Plasmodium falciparum Malaria: First-line curative treatment for acute, uncomplicated malaria caused by P. falciparum or mixed species infections containing P. falciparum.

• Multi-Drug Resistant Malaria: Highly effective against P. falciparum strains that exhibit resistance to older antimalarial monotherapies such as chloroquine, sulfadoxine-pyrimethamine (Fansidar), or quinine.

• Treatment of Non-falciparum Blood-Stage Parasites: Effective against erythrocytic schizonts of Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae (radical cure for dormant liver hypnozoites in P. vivax and P. ovale requires adjunct therapy with primaquine or tafenoquine).

Key Product Specifications & Dosing Forms

Critical Safety Guidelines & Precautions

• Take on an Empty Stomach or Low-Fat Meal: Unlike lumefantrine-based ACTs (which require high-fat meals), piperaquine bioavailability increases substantially when co-administered with dietary fats. Excessive absorption can raise plasma drug levels and increase the risk of cardiac side effects.

• QTc Prolongation Warning: Piperaquine has the potential to prolong the QTc interval on an ECG. Avoid co-administration with other QT-prolonging drugs (e.g., macrolide antibiotics, antiarrhythmics, quinine, halofantrine) or in patients with known congenital long QT syndrome or severe electrolyte imbalances.

• Re-Dosing Protocol for Vomiting: If vomiting occurs within 30 to 60 minutes of taking a dose, re-administer a full replacement dose immediately. If persistent vomiting prevents oral retention, switch immediately to parenteral antimalarial therapy (e.g., IV or IM artesunate).

• Not for Severe/Complicated Malaria: Contraindicated as monotherapy for severe or complicated malaria (e.g., cerebral malaria, severe malarial anemia, pulmonary edema). Severe cases require immediate intravenous antimalarial intervention.

• Prophylaxis Restriction: Zomal TS is strictly a therapeutic curative agent and must never be used for malaria prophylaxis.